Mesenchymal stromal cells plus basiliximab, calcineurin inhibitor as treatment of steroid-resistant acute graft-versus-host disease: a multicenter, randomized, phase 3, open-label trial.
Ke ZhaoRen LinZhiping FanXiaoyong ChenYu WangFen HuangNa XuXi ZhangXin ZhangLi XuanShunqing WangDongjun LinLan DengDanian NieJianyu WengYonghua LiXiaohui ZhangYuhua LiA P XiangQi-Fa LiuPublished in: Journal of hematology & oncology (2022)
MSCs plus second-line treatments increase the efficacy of SR aGVHD, decrease drug toxicity of second-line drugs and cGVHD without increasing relapse, and are well-tolerated. MSCs could be recommended as a second-line treatment option for aGVHD patients. Trial registration clinicaltrials.gov identifier: NCT02241018. Registration date: September 16, 2014, https://clinicaltrials.gov/ct2/show/NCT02241018 .
Keyphrases
- open label
- phase iii
- phase ii
- clinical trial
- study protocol
- double blind
- end stage renal disease
- newly diagnosed
- bone marrow
- drug induced
- placebo controlled
- peritoneal dialysis
- liver failure
- cross sectional
- phase ii study
- emergency department
- respiratory failure
- image quality
- magnetic resonance
- electronic health record
- smoking cessation
- patient reported outcomes
- dual energy